IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.912
EU - Europa 1.279
AS - Asia 1.192
SA - Sud America 181
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 7.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.884
SG - Singapore 638
IT - Italia 318
CN - Cina 262
RU - Federazione Russa 191
DE - Germania 177
UA - Ucraina 171
BR - Brasile 164
IE - Irlanda 80
IN - India 76
VN - Vietnam 65
GB - Regno Unito 44
KR - Corea 44
SE - Svezia 44
FI - Finlandia 43
FR - Francia 33
TR - Turchia 33
BE - Belgio 32
CZ - Repubblica Ceca 30
AT - Austria 26
NL - Olanda 23
CA - Canada 16
CH - Svizzera 15
HK - Hong Kong 15
RO - Romania 13
IR - Iran 10
PL - Polonia 9
JP - Giappone 8
LT - Lituania 7
AR - Argentina 6
IQ - Iraq 6
MX - Messico 5
PK - Pakistan 5
ZA - Sudafrica 5
BD - Bangladesh 4
EC - Ecuador 4
EE - Estonia 4
EG - Egitto 4
LA - Repubblica Popolare Democratica del Laos 4
TG - Togo 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
AZ - Azerbaigian 3
DK - Danimarca 3
ES - Italia 3
EU - Europa 3
LV - Lettonia 3
PA - Panama 3
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
CO - Colombia 2
IL - Israele 2
JM - Giamaica 2
LB - Libano 2
MA - Marocco 2
AU - Australia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
DZ - Algeria 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
ID - Indonesia 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 7.590
Salva come PNG Salva come JPEG
Città #
Fairfield 716
Ashburn 495
Chandler 446
Singapore 427
Woodbridge 346
Seattle 300
Houston 263
Wilmington 241
Cambridge 227
Ann Arbor 207
Boardman 145
Dearborn 115
Jacksonville 98
Beijing 95
Princeton 76
Dublin 75
Dong Ket 64
New York 56
Udine 51
Seoul 43
Los Angeles 41
San Diego 39
Washington 34
Brussels 29
Izmir 27
Martignacco 26
Redmond 26
Brno 25
Munich 24
Ogden 24
Dallas 23
Des Moines 23
Frankfurt am Main 23
Belluno 18
Nuremberg 16
Santa Clara 16
Zurich 15
London 14
Phoenix 14
Guangzhou 13
Helsinki 13
Hong Kong 13
Milan 13
Falls Church 12
Nanjing 12
Norwalk 12
Düsseldorf 11
Hyderabad 11
Trieste 11
Vienna 11
Lauterbourg 10
Leawood 10
Naples 10
São Paulo 10
Arezzo 9
Rome 9
San Francisco 9
Timisoara 9
Hefei 8
Shanghai 8
Warsaw 8
Augusta 7
Jinan 7
Newark 7
Tokyo 6
Toronto 6
Xi'an 6
Belo Horizonte 5
Brooklyn 5
Codroipo 5
Cordenons 5
Genoa 5
Jiaxing 5
Kunming 5
Lappeenranta 5
Nanchang 5
Scafati 5
Simi Valley 5
Stockholm 5
Venice 5
Amsterdam 4
Ardabil 4
Bovisio-Masciago 4
Cairo 4
Campinas 4
Charlotte 4
Edinburgh 4
Fuzhou 4
Lomé 4
Menlo Park 4
Moscow 4
Ottawa 4
Paris 4
Portsmouth 4
Redwood City 4
Shenzhen 4
Tallinn 4
Turku 4
Vientiane 4
Wenzhou 4
Totale 5.359
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 184
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 150
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 149
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 144
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 140
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 137
Pattern of metastasis and outcome in patients with breast cancer 137
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 129
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 127
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 126
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 126
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 124
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 122
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 122
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 120
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 119
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 115
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 113
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 112
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 109
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 109
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 108
Do platinum salts fit all triple negative breast cancers? 108
Determinants of Last-line Treatment in Metastatic Breast Cancer 106
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 106
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 105
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 104
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 103
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 102
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 101
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 101
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 100
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 100
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 98
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 97
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 96
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 95
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 92
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 90
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 89
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 89
Risk factors and survival outcomes in patients with brain metastases from breast cancer 84
null 84
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 82
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 81
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 81
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 80
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 79
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 79
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 79
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 79
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 78
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 68
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 67
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 66
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 64
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 64
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 64
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 63
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 62
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 61
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 60
Time to surgery after neoadjuvant chemotherapy for early breast cancer 59
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 58
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 56
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 56
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 55
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 54
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 49
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 49
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 47
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 47
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 44
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 44
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 44
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 40
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 39
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 39
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 38
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 38
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 37
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 35
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 35
Landscape of circulating tumour DNA in metastatic breast cancer 33
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 30
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 29
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 28
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 28
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 27
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 27
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 26
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 26
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 24
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 24
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis 24
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 23
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer 23
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 22
Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II 22
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer 21
Totale 7.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 0 0 0 0 0 0 0 0 0 0 0 59
2020/20211.306 52 131 91 229 114 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.045 130 158 97 110 189 121 175 149 315 173 417 11
Totale 8.013